Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 531

1.

Nucleophilicity of Glutathione: A Link to Michael Acceptor Reactivities.

Mayer RJ, Ofial AR.

Angew Chem Int Ed Engl. 2019 Sep 27. doi: 10.1002/anie.201909803. [Epub ahead of print]

PMID:
31560405
2.

Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance).

Yuan C, Sato K, Hollis BW, Zhang S, Niedzwieck D, Ou FS, Chang IW, O'Neil BH, Innocenti F, Lenz HJ, Blanke CD, Goldberg RM, Venook AP, Mayer RJ, Fuchs CS, Meyerhardt JA, Ng K.

Clin Cancer Res. 2019 Sep 23. pii: clincanres.0877.2019. doi: 10.1158/1078-0432.CCR-19-0877. [Epub ahead of print]

PMID:
31548349
3.

NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 2.2019.

Gupta S, Provenzale D, Llor X, Halverson AL, Grady W, Chung DC, Haraldsdottir S, Markowitz AJ, Slavin TP Jr, Hampel H; CGC, Ness RM, Weiss JM, Ahnen DJ, Chen LM, Cooper G, Early DS, Giardiello FM, Hall MJ, Hamilton SR, Kanth P, Klapman JB, Lazenby AJ, Lynch PM, Mayer RJ, Mikkelson J; CGC, Peter S, Regenbogen SE, Dwyer MA; CGC, Ogba N.

J Natl Compr Canc Netw. 2019 Sep 1;17(9):1032-1041. doi: 10.6004/jnccn.2019.0044.

PMID:
31487681
4.

Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405.

Guercio BJ, Zhang S, Ou FS, Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Sato K, Ng K, Van Blarigan E, Mayer RJ, Blanke CD, O'Reilly EM, Fuchs CS, Meyerhardt JA.

J Clin Oncol. 2019 Oct 10;37(29):2620-2631. doi: 10.1200/JCO.19.01019. Epub 2019 Aug 13.

PMID:
31408415
5.

Ambident Reactivity of Phenolate Anions Revisited: A Quantitative Approach to Phenolate Reactivities.

Mayer RJ, Breugst M, Hampel N, Ofial AR, Mayr H.

J Org Chem. 2019 Jul 19;84(14):8837-8858. doi: 10.1021/acs.joc.9b01485. Epub 2019 Jun 26.

PMID:
31241938
6.

Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance).

Lenz HJ, Ou FS, Venook AP, Hochster HS, Niedzwiecki D, Goldberg RM, Mayer RJ, Bertagnolli MM, Blanke CD, Zemla T, Qu X, Wirapati P, Tejpar S, Innocenti F, Kabbarah O.

J Clin Oncol. 2019 Aug 1;37(22):1876-1885. doi: 10.1200/JCO.18.02258. Epub 2019 May 1.

PMID:
31042420
7.

Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial.

Kosumi K, Hamada T, Zhang S, Liu L, da Silva A, Koh H, Twombly TS, Mima K, Morikawa T, Song M, Nowak JA, Nishihara R, Saltz LB, Niedzwiecki D, Ou FS, Zemla T, Mayer RJ, Baba H, Ng K, Giannakis M, Zhang X, Wu K, Giovannucci EL, Chan AT, Fuchs CS, Meyerhardt JA, Ogino S.

Eur J Cancer. 2019 Apr;111:82-93. doi: 10.1016/j.ejca.2019.01.022. Epub 2019 Mar 1.

PMID:
30826660
8.

Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance).

Morales-Oyarvide V, Yuan C, Babic A, Zhang S, Niedzwiecki D, Brand-Miller JC, Sampson-Kent L, Ye X, Li Y, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Wu K, Willett WC, Giovannucci EL, Wolpin BM, Meyerhardt JA, Fuchs CS, Ng K.

J Natl Cancer Inst. 2019 Feb 1;111(2):170-179. doi: 10.1093/jnci/djy098.

9.

Biomimetic Approach Toward Enterocin and Deoxyenterocin.

Rizzo A, Mayer RJ, Trauner D.

J Org Chem. 2019 Feb 1;84(3):1162-1175. doi: 10.1021/acs.joc.8b02273. Epub 2019 Jan 18.

PMID:
30520624
10.

Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer.

Mayer RJ, Hochster HS, Cohen SJ, Winkler R, Makris L, Grothey A.

Cancer Chemother Pharmacol. 2018 Dec;82(6):961-969. doi: 10.1007/s00280-018-3686-5. Epub 2018 Oct 22.

PMID:
30350179
11.

NCCN Guidelines Insights: Colorectal Cancer Screening, Version 1.2018.

Provenzale D, Gupta S, Ahnen DJ, Markowitz AJ, Chung DC, Mayer RJ, Regenbogen SE, Blanco AM, Bray T, Cooper G, Early DS, Ford JM, Giardiello FM, Grady W, Hall MJ, Halverson AL, Hamilton SR, Hampel H, Klapman JB, Larson DW, Lazenby AJ, Llor X, Lynch PM, Mikkelson J, Ness RM, Slavin TP, Sugandha S, Weiss JM, Dwyer MA, Ogba N.

J Natl Compr Canc Netw. 2018 Aug;16(8):939-949. doi: 10.6004/jnccn.2018.0067.

PMID:
30099370
12.

Dietary Fat Intake after Colon Cancer Diagnosis in Relation to Cancer Recurrence and Survival: CALGB 89803 (Alliance).

Van Blarigan EL, Ou FS, Niedzwiecki D, Zhang S, Fuchs CS, Saltz L, Mayer RJ, Venook A, Ogino S, Song M, Benson A, Hantel A, Atkins JN, Giovannucci EL, Meyerhardt JA.

Cancer Epidemiol Biomarkers Prev. 2018 Oct;27(10):1227-1230. doi: 10.1158/1055-9965.EPI-18-0487. Epub 2018 Jul 23.

13.

Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance).

Guercio BJ, Zhang S, Niedzwiecki D, Li Y, Babic A, Morales-Oyarvide V, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Zoltick ES, Stampfer M, Ng K, Wu K, Willett WC, Giovannucci EL, Meyerhardt JA, Fuchs CS.

PLoS One. 2018 Jul 19;13(7):e0199244. doi: 10.1371/journal.pone.0199244. eCollection 2018.

14.

Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.

Aguirre AJ, Nowak JA, Camarda ND, Moffitt RA, Ghazani AA, Hazar-Rethinam M, Raghavan S, Kim J, Brais LK, Ragon D, Welch MW, Reilly E, McCabe D, Marini L, Anderka K, Helvie K, Oliver N, Babic A, Da Silva A, Nadres B, Van Seventer EE, Shahzade HA, St Pierre JP, Burke KP, Clancy T, Cleary JM, Doyle LA, Jajoo K, McCleary NJ, Meyerhardt JA, Murphy JE, Ng K, Patel AK, Perez K, Rosenthal MH, Rubinson DA, Ryou M, Shapiro GI, Sicinska E, Silverman SG, Nagy RJ, Lanman RB, Knoerzer D, Welsch DJ, Yurgelun MB, Fuchs CS, Garraway LA, Getz G, Hornick JL, Johnson BE, Kulke MH, Mayer RJ, Miller JW, Shyn PB, Tuveson DA, Wagle N, Yeh JJ, Hahn WC, Corcoran RB, Carter SL, Wolpin BM.

Cancer Discov. 2018 Sep;8(9):1096-1111. doi: 10.1158/2159-8290.CD-18-0275. Epub 2018 Jun 14.

15.

Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance).

Brown JC, Zhang S, Niedzwiecki D, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Li Y, Zhang X, Ng K, Willett WC, Giovannucci EL, Fuchs CS, Meyerhardt JA.

JNCI Cancer Spectr. 2018 Feb;2(2):pky017. doi: 10.1093/jncics/pky017. Epub 2018 May 30.

16.

Nucleophilic Reactivities of Bleach Reagents.

Mayer RJ, Ofial AR.

Org Lett. 2018 May 18;20(10):2816-2820. doi: 10.1021/acs.orglett.8b00645. Epub 2018 May 9.

PMID:
29741385
17.

Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis: The CALGB 89803/Alliance Trial.

Van Blarigan EL, Fuchs CS, Niedzwiecki D, Zhang S, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Giovannucci EL, Ng K, Meyerhardt JA.

JAMA Oncol. 2018 Jun 1;4(6):783-790. doi: 10.1001/jamaoncol.2018.0126.

18.

Alternative rib bone biopsy measurements to estimate changes in skeletal mineral reserves in cattle.

Dixon RM, Coates DB, Mayer RJ, Miller CP.

Animal. 2019 Jan;13(1):119-126. doi: 10.1017/S175173111800068X. Epub 2018 Apr 19.

PMID:
29669613
19.

Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance).

Fadelu T, Zhang S, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson AB, Atienza DM, Messino M, Kindler HL, Venook A, Ogino S, Ng K, Wu K, Willett W, Giovannucci E, Meyerhardt J, Bao Y, Fuchs CS.

J Clin Oncol. 2018 Apr 10;36(11):1112-1120. doi: 10.1200/JCO.2017.75.5413. Epub 2018 Feb 28.

20.

Which Factors Control the Nucleophilic Reactivities of Enamines?

Timofeeva DS, Mayer RJ, Mayer P, Ofial AR, Mayr H.

Chemistry. 2018 Apr 17;24(22):5901-5910. doi: 10.1002/chem.201705962. Epub 2018 Mar 25.

PMID:
29388720
21.

Marine ω-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance).

Van Blarigan EL, Fuchs CS, Niedzwiecki D, Ye X, Zhang S, Song M, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Giovannucci EL, Meyerhardt JA.

Cancer Epidemiol Biomarkers Prev. 2018 Apr;27(4):438-445. doi: 10.1158/1055-9965.EPI-17-0689. Epub 2018 Jan 22.

22.

The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer.

Van Cutsem E, Mayer RJ, Laurent S, Winkler R, Grávalos C, Benavides M, Longo-Munoz F, Portales F, Ciardiello F, Siena S, Yamaguchi K, Muro K, Denda T, Tsuji Y, Makris L, Loehrer P, Lenz HJ, Ohtsu A; RECOURSE Study Group.

Eur J Cancer. 2018 Feb;90:63-72. doi: 10.1016/j.ejca.2017.10.009. Epub 2017 Dec 21.

23.

NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 3.2017.

Gupta S, Provenzale D, Regenbogen SE, Hampel H, Slavin TP, Hall MJ, Llor X, Chung DC, Ahnen DJ, Bray T, Cooper G, Early DS, Ford JM, Giardiello FM, Grady W, Halverson AL, Hamilton SR, Klapman JB, Larson DW, Lazenby AJ, Lynch PM, Markowitz AJ, Mayer RJ, Ness RM, Samadder NJ, Shike M, Sugandha S, Weiss JM, Dwyer MA, Ogba N.

J Natl Compr Canc Netw. 2017 Dec;15(12):1465-1475. doi: 10.6004/jnccn.2017.0176.

PMID:
29223984
24.

Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial.

Van Cutsem E, Falcone A, Garcia-Carbonero R, Komatsu Y, Pastorino A, Peeters M, Shimada Y, Yamazaki K, Yoshino T, Zaniboni A, Amellal N, Kanehisa A, Winkler R, Makris L, Mayer RJ, Ohtsu A, Tabernero J.

ESMO Open. 2017 Nov 23;2(5):e000261. doi: 10.1136/esmoopen-2017-000261. eCollection 2017.

25.

QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer.

Tabernero J, Van Cutsem E, Ohtsu A, Amellal N, Cadour S, Fougeray R, Haffemayer B, Mayer RJ.

ESMO Open. 2017 Nov 23;2(5):e000284. doi: 10.1136/esmoopen-2017-000284. eCollection 2017.

26.

Integrated safety summary for trifluridine/tipiracil (TAS-102).

Falcone A, Ohtsu A, Van Cutsem E, Mayer RJ, Buscaglia M, Bendell JC, Kopetz S, Bebeau P, Yoshino T.

Anticancer Drugs. 2018 Jan;29(1):89-96. doi: 10.1097/CAD.0000000000000554.

PMID:
29176395
27.

Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance).

Fuchs CS, Niedzwiecki D, Mamon HJ, Tepper JE, Ye X, Swanson RS, Enzinger PC, Haller DG, Dragovich T, Alberts SR, Bjarnason GA, Willett CG, Gunderson LL, Goldberg RM, Venook AP, Ilson D, O'Reilly E, Ciombor K, Berg DJ, Meyerhardt J, Mayer RJ.

J Clin Oncol. 2017 Nov 10;35(32):3671-3677. doi: 10.1200/JCO.2017.74.2130. Epub 2017 Oct 4.

28.

Solvation Accounts for the Counterintuitive Nucleophilicity Ordering of Peroxide Anions.

Mayer RJ, Tokuyasu T, Mayer P, Gomar J, Sabelle S, Mennucci B, Mayr H, Ofial AR.

Angew Chem Int Ed Engl. 2017 Oct 16;56(43):13279-13282. doi: 10.1002/anie.201707086. Epub 2017 Sep 18.

PMID:
28815833
29.

Epithelial desquamation observed in a phase I study of an oral cathepsin C inhibitor (GSK2793660).

Miller BE, Mayer RJ, Goyal N, Bal J, Dallow N, Boyce M, Carpenter D, Churchill A, Heslop T, Lazaar AL.

Br J Clin Pharmacol. 2017 Dec;83(12):2813-2820. doi: 10.1111/bcp.13398. Epub 2017 Sep 20.

30.

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.

Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH, Atkins JN, Berry S, Polite BN, O'Reilly EM, Goldberg RM, Hochster HS, Schilsky RL, Bertagnolli MM, El-Khoueiry AB, Watson P, Benson AB 3rd, Mulkerin DL, Mayer RJ, Blanke C.

JAMA. 2017 Jun 20;317(23):2392-2401. doi: 10.1001/jama.2017.7105.

31.

Danirixin: A Reversible and Selective Antagonist of the CXC Chemokine Receptor 2.

Busch-Petersen J, Carpenter DC, Burman M, Foley J, Hunsberger GE, Kilian DJ, Salmon M, Mayer RJ, Yonchuk JG, Tal-Singer R.

J Pharmacol Exp Ther. 2017 Aug;362(2):338-346. doi: 10.1124/jpet.117.240705. Epub 2017 Jun 13.

PMID:
28611093
32.

Development and Validation of the PREMM5 Model for Comprehensive Risk Assessment of Lynch Syndrome.

Kastrinos F, Uno H, Ukaegbu C, Alvero C, McFarland A, Yurgelun MB, Kulke MH, Schrag D, Meyerhardt JA, Fuchs CS, Mayer RJ, Ng K, Steyerberg EW, Syngal S.

J Clin Oncol. 2017 Jul 1;35(19):2165-2172. doi: 10.1200/JCO.2016.69.6120. Epub 2017 May 10.

33.

Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance).

Fuchs MA, Yuan C, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Innocenti F, Warren RS, Bertagnolli MM, Ogino S, Giovannucci EL, Horvath E, Meyerhardt JA, Ng K.

Ann Oncol. 2017 Jun 1;28(6):1359-1367. doi: 10.1093/annonc/mdx109.

34.

Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer.

Yurgelun MB, Kulke MH, Fuchs CS, Allen BA, Uno H, Hornick JL, Ukaegbu CI, Brais LK, McNamara PG, Mayer RJ, Schrag D, Meyerhardt JA, Ng K, Kidd J, Singh N, Hartman AR, Wenstrup RJ, Syngal S.

J Clin Oncol. 2017 Apr 1;35(10):1086-1095. doi: 10.1200/JCO.2016.71.0012. Epub 2017 Jan 30.

35.

Reply to L. Casadaban et al.

Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, Innocenti F.

J Clin Oncol. 2017 Apr 20;35(12):1373-1374. doi: 10.1200/JCO.2016.71.2646. Epub 2017 Jan 23. No abstract available.

PMID:
28113023
36.

Mechanisms of Vascular Dysfunction in COPD and Effects of a Novel Soluble Epoxide Hydrolase Inhibitor in Smokers.

Yang L, Cheriyan J, Gutterman DD, Mayer RJ, Ament Z, Griffin JL, Lazaar AL, Newby DE, Tal-Singer R, Wilkinson IB.

Chest. 2017 Mar;151(3):555-563. doi: 10.1016/j.chest.2016.10.058. Epub 2016 Nov 21.

37.

A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803.

Niedzwiecki D, Hasson RM, Lenz HJ, Ye C, Redston M, Ogino S, Fuchs CS, Compton CC, Mayer RJ, Goldberg RM, Colacchio TA, Saltz LB, Warren RS, Bertagnolli MM.

Oncologist. 2017 Jan;22(1):107-114. doi: 10.1634/theoncologist.2016-0215. Epub 2016 Nov 7.

38.

Genetic/Familial High-Risk Assessment: Colorectal Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.

Provenzale D, Gupta S, Ahnen DJ, Bray T, Cannon JA, Cooper G, David DS, Early DS, Erwin D, Ford JM, Giardiello FM, Grady W, Halverson AL, Hamilton SR, Hampel H, Ismail MK, Klapman JB, Larson DW, Lazenby AJ, Lynch PM, Mayer RJ, Ness RM, Regenbogen SE, Samadder NJ, Shike M, Steinbach G, Weinberg D, Dwyer M, Darlow S.

J Natl Compr Canc Netw. 2016 Aug;14(8):1010-30.

PMID:
27496117
39.

Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance).

Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, Innocenti F.

J Clin Oncol. 2016 Sep 1;34(25):3047-53. doi: 10.1200/JCO.2015.65.4699. Epub 2016 Jul 18.

40.

CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.

Enzinger PC, Burtness BA, Niedzwiecki D, Ye X, Douglas K, Ilson DH, Villaflor VM, Cohen SJ, Mayer RJ, Venook A, Benson AB 3rd, Goldberg RM.

J Clin Oncol. 2016 Aug 10;34(23):2736-42. doi: 10.1200/JCO.2015.65.5092. Epub 2016 Jul 5.

41.

Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor.

Lazaar AL, Yang L, Boardley RL, Goyal NS, Robertson J, Baldwin SJ, Newby DE, Wilkinson IB, Tal-Singer R, Mayer RJ, Cheriyan J.

Br J Clin Pharmacol. 2016 May;81(5):971-9. doi: 10.1111/bcp.12855. Epub 2016 Jan 17.

42.

Erratum to: Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer.

Bendell JC, Rosen LS, Mayer RJ, Goldman JW, Infante JR, Benedetti F, Lin D, Mizuguchi H, Zergebel C, Patel MR.

Cancer Chemother Pharmacol. 2016 Feb;77(2):439. doi: 10.1007/s00280-015-2890-9. No abstract available.

43.

Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer.

Bendell JC, Rosen LS, Mayer RJ, Goldman JW, Infante JR, Benedetti F, Lin D, Mizuguchi H, Zergebel C, Patel MR.

Cancer Chemother Pharmacol. 2015 Nov;76(5):925-32. doi: 10.1007/s00280-015-2850-4. Epub 2015 Sep 14. Erratum in: Cancer Chemother Pharmacol. 2016 Feb;77(2):439.

44.

Colorectal Cancer Screening, Version 1.2015.

Provenzale D, Jasperson K, Ahnen DJ, Aslanian H, Bray T, Cannon JA, David DS, Early DS, Erwin D, Ford JM, Giardiello FM, Gupta S, Halverson AL, Hamilton SR, Hampel H, Ismail MK, Klapman JB, Larson DW, Lazenby AJ, Lynch PM, Mayer RJ, Ness RM, Rao MS, Regenbogen SE, Shike M, Steinbach G, Weinberg D, Dwyer MA, Freedman-Cass DA, Darlow S; National comprehensive cancer netwok.

J Natl Compr Canc Netw. 2015 Aug;13(8):959-68; quiz 968.

PMID:
26285241
45.

Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance).

Guercio BJ, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Hu FB, Ogino S, Wu K, Willett WC, Giovannucci EL, Meyerhardt JA, Fuchs CS.

J Clin Oncol. 2015 Nov 1;33(31):3598-607. doi: 10.1200/JCO.2015.61.5062. Epub 2015 Aug 17.

46.

Circulating soluble receptor for advanced glycation end products (sRAGE) as a biomarker of emphysema and the RAGE axis in the lung.

Yonchuk JG, Silverman EK, Bowler RP, Agustí A, Lomas DA, Miller BE, Tal-Singer R, Mayer RJ.

Am J Respir Crit Care Med. 2015 Oct 1;192(7):785-92. doi: 10.1164/rccm.201501-0137PP. Review.

PMID:
26132989
47.

Randomized trial of TAS-102 for refractory metastatic colorectal cancer.

Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A; RECOURSE Study Group.

N Engl J Med. 2015 May 14;372(20):1909-19. doi: 10.1056/NEJMoa1414325.

48.

Gene expression changes caused by the p38 MAPK inhibitor dilmapimod in COPD patients: analysis of blood and sputum samples from a randomized, placebo-controlled clinical trial.

Betts JC, Mayer RJ, Tal-Singer R, Warnock L, Clayton C, Bates S, Hoffman BE, Larminie C, Singh D.

Pharmacol Res Perspect. 2015 Feb;3(1):e00094. doi: 10.1002/prp2.94. Epub 2014 Dec 9.

49.

Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation.

Bohanes P, Rankin CJ, Blanke CD, Winder T, Ulrich CM, Smalley SR, Rich TA, Martensen JA, Benson AB 3rd, Mayer RJ, Cripps CM, Danenberg K, Makar KW, Zhang W, Benedetti JK, Lenz HJ.

Clin Cancer Res. 2015 Apr 1;21(7):1583-90. doi: 10.1158/1078-0432.CCR-14-0857. Epub 2015 Jan 14.

50.

Aspirin and COX-2 inhibitor use in patients with stage III colon cancer.

Ng K, Meyerhardt JA, Chan AT, Sato K, Chan JA, Niedzwiecki D, Saltz LB, Mayer RJ, Benson AB 3rd, Schaefer PL, Whittom R, Hantel A, Goldberg RM, Venook AP, Ogino S, Giovannucci EL, Fuchs CS.

J Natl Cancer Inst. 2014 Nov 27;107(1):345. doi: 10.1093/jnci/dju345. Print 2015 Jan.

Supplemental Content

Loading ...
Support Center